Cook Medical's Zilver® PTX® Drug-Eluting Stent selected as a top emerging health technology in Canada

Bloomington, Ind. — As announced at the 2014 Canadian Agency for Drugs and Technologies in Health (CADTH) symposium, the Canadian Network for Environmental Scanning in Health (CNESH) has selected Cook Medical’s Zilver® PTX® drug-eluting peripheral stent as a top 10 game-changing health technology for 2014. The CNESH top 10 list is designed to encourage the adoption and use of effective, safe health technologies in Canada.

Zilver PTX is the first self-expanding, drug-eluting stent available to help treat peripheral arterial disease (PAD) in the superficial femoral artery (SFA) in Canada. Approximately 800,000 Canadians have PAD, a growing and pervasive disease. According to CADTH, PAD occurs in four percent of Canadians older than 40, increasing to 20 percent in individuals over the age of 75. Worldwide, recent reports have shown that PAD has reached epidemic levels in developed countries, with 38 million new cases reported in the last 10 years.

“Now that we have over four years of clinical data^[1] showing a long-term drug effect compared to uncoated stents, the advantage of treating SFA blockages with drug-eluting stents is clear,” said Mark Breedlove, vice president and global leader of Cook Medical’s Peripheral Intervention division. “It’s fantastic to see CNESH highlight technologies that positively impact patient outcomes and health care costs by reducing the number of repeat procedures.”

Zilver PTX entered the European market in August 2009, the US market in November 2012, and is the first drug-eluting stent indicated to treat peripheral arterial disease in the SFA in Canada. Since its release, the stent has been used to treat more than 25,000 patients in Europe, Asia, North and South America, Australia, New Zealand and India.

^[1] Data on file with Cook Medical

Source: Cook Medical